JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 Jul 2024
30 Jul 2024
Historique:
received:
13
12
2023
accepted:
10
07
2024
medline:
31
7
2024
pubmed:
31
7
2024
entrez:
30
7
2024
Statut:
epublish
Résumé
The interleukin (IL)-23 pathway is a pathogenic driver in psoriasis, psoriatic arthritis, and inflammatory bowel disease. Currently, no oral therapeutics selectively target this pathway. JNJ-77242113 is a peptide targeting the IL-23 receptor with high affinity (K
Identifiants
pubmed: 39080319
doi: 10.1038/s41598-024-67371-5
pii: 10.1038/s41598-024-67371-5
doi:
Substances chimiques
Interleukin-23
0
Receptors, Interleukin
0
IL23R protein, human
0
Peptides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17515Informations de copyright
© 2024. The Author(s).
Références
Bloch, Y. et al. Structural activation of pro-inflammatory human cytokine IL-23 by cognate IL-23 receptor enables recruitment of the shared receptor IL-12Rbeta1. Immunity 48(45–58), e6 (2018).
Elloso, M. M., Gomez-Angelats, M. & Fourie, A. M. Targeting the Th17 pathway in psoriasis. J. Leukoc. Biol. 92, 1187–1197 (2012).
doi: 10.1189/jlb.0212101
pubmed: 22962689
Kock, K. et al. Preclinical development of AMG 139, a human antibody specifically targeting IL-23. Br. J. Pharmacol. 172, 159–172 (2015).
doi: 10.1111/bph.12904
pubmed: 25205227
Parham, C. et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168, 5699–5708 (2002).
doi: 10.4049/jimmunol.168.11.5699
pubmed: 12023369
Fragoulis, G. E. & Siebert, S. The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis. Musculoskelet. Care 20(Suppl 1), S12–S21 (2022).
Geremia, A. et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J. Exp. Med. 208, 1127–1133 (2011).
doi: 10.1084/jem.20101712
pubmed: 21576383
pmcid: 3173242
Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E. & Barker, J. Psoriasis. Lancet 397, 1301–1315 (2021).
doi: 10.1016/S0140-6736(20)32549-6
pubmed: 33812489
Neurath, M. F. IL-23: A master regulator in Crohn disease. Nat. Med. 13, 26–28 (2007).
doi: 10.1038/nm0107-26
pubmed: 17206128
Yen, D. et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Investig. 116, 1310–1316 (2006).
doi: 10.1172/JCI21404
pubmed: 16670770
pmcid: 1451201
Buonocore, S. et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464, 1371–1375 (2010).
doi: 10.1038/nature08949
pubmed: 20393462
pmcid: 3796764
Hue, S. et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med. 203, 2473–2483 (2006).
doi: 10.1084/jem.20061099
pubmed: 17030949
pmcid: 2118132
Imamura, E. et al. Anti-IL-23 receptor monoclonal antibody prevents CD4(+) T cell-mediated colitis in association with decreased systemic Th1 and Th17 responses. Eur. J. Pharmacol. 824, 163–169 (2018).
doi: 10.1016/j.ejphar.2018.01.045
pubmed: 29391156
Kullberg, M. C. et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J. Exp. Med. 203, 2485–2494 (2006).
doi: 10.1084/jem.20061082
pubmed: 17030948
pmcid: 2118119
Uhlig, H. H. et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 25, 309–318 (2006).
doi: 10.1016/j.immuni.2006.05.017
pubmed: 16919486
Chan, J. R. et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. 203, 2577–2587 (2006).
doi: 10.1084/jem.20060244
pubmed: 17074928
pmcid: 2118145
Nakajima, K. et al. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J. Immunol. 186, 4481–4489 (2011).
doi: 10.4049/jimmunol.1000148
pubmed: 21346238
Duerr, R. H. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461–1463 (2006).
doi: 10.1126/science.1135245
pubmed: 17068223
pmcid: 4410764
Pidasheva, S. et al. Functional studies on the IBD susceptibility gene IL23R implicate reduced receptor function in the protective genetic variant R381Q. PLoS One 6, e25038 (2011).
doi: 10.1371/journal.pone.0025038
pubmed: 22022372
pmcid: 3192060
Sarin, R., Wu, X. & Abraham, C. Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T-cell functional responses. Proc. Natl. Acad. Sci. U. S. A. 108, 9560–9565 (2011).
doi: 10.1073/pnas.1017854108
pubmed: 21606346
pmcid: 3111257
Silverberg, M. S. et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat. Genet. 41, 216–220 (2009).
doi: 10.1038/ng.275
pubmed: 19122664
pmcid: 2652837
Cargill, M. et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80, 273–290 (2007).
doi: 10.1086/511051
pubmed: 17236132
Kashani, A. & Schwartz, D. A. The expanding role of anti-IL-12 and/or anti-IL-23 antibodies in the treatment of inflammatory bowel disease. Gastroenterol. Hepatol. (N. Y.) 15, 255–265 (2019).
pubmed: 31360139
Moschen, A. R., Tilg, H. & Raine, T. IL-12, IL-23 and IL-17 in IBD: Immunobiology and therapeutic targeting. Nat. Rev. Gastroenterol. Hepatol. 16, 185–196 (2019).
doi: 10.1038/s41575-018-0084-8
pubmed: 30478416
Neurath, M. F. IL-23 in inflammatory bowel diseases and colon cancer. Cytokine Growth Factor Rev. 45, 1–8 (2019).
doi: 10.1016/j.cytogfr.2018.12.002
pubmed: 30563755
Yang, K., Oak, A. S. W. & Elewski, B. E. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: A comprehensive review. Am. J. Clin. Dermatol. 22, 173–192 (2021).
doi: 10.1007/s40257-020-00578-0
pubmed: 33301128
Bissonnette, R. et al. An oral interleukin-23-receptor antagonist peptide for plaque psoriasis. N. Engl. J. Med. 390, 510–521 (2024).
doi: 10.1056/NEJMoa2308713
pubmed: 38324484
Drucker, D. J. Advances in oral peptide therapeutics. Nat. Rev. Drug Discov. 19, 277–289 (2020).
doi: 10.1038/s41573-019-0053-0
pubmed: 31848464
Burke, J. R. et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aaw1736 (2019).
doi: 10.1126/scitranslmed.aaw1736
pubmed: 31341059
pmcid: 6830438
Shah, D. K. & Betts, A. M. Antibody biodistribution coefficients: Inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. MAbs 5, 297–305 (2013).
doi: 10.4161/mabs.23684
pubmed: 23406896
pmcid: 3893240
STELARA (ustekinumab) prescribing information. Centocor Ortho Biotech Inc. Horsham, PA (2009).
TREMFYA (guselkumab) injection for subcutaneous use. Janssen Biotech Inc. Horsham PA (2010).
SKYRIZI (risankizumab-rzaa) injection for subcutaneous or intravenouse use. AbbVie Biotechnology Ltd. North Chicago IL (2022).